Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
Track: The Visual Abstract
Can rivaroxaban reduce cardiovascular events in advanced CKD?
The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high cardiovascular risk.
Check out the latest VA and review the next #NephJC.
Is TRPC6 inhibition for FSGS a trick or a treat?
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease?
To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
A VALIANT effort to combat complement disorders with pegcetacoplan
Top Stories in Nephrology 2025
TenPosts PISCES
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
In ESRD is spironolactone an overACHIEVEr?
Las Perspectivas del estudio CRIC: el Resumen Visual
Basado en los datos del estudio CRIC, este análisis profundiza en si esa discordancia (TFGe dif) es solo “ruido”… o una señal clínica que hemos estado ignorando.
Echale un vistazo al resumen visual realizado por el equipo de internos de #NephJC Dr Sai Vani Yellampalli y Akshaya Jayachandran
Insights from the CRIC Study: Visual Abstract
Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing.
Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran. Great team work!!!